What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
复制标题
非酒精性脂肪性肝病（NAFLD）治疗新进展
DOI：
10.3390/jcm12051852
复制
发表时间：
2023-02-26
影响因子：
3.9
通讯作者：
Pietras, Tadeusz
中科院分区：
文献类型：
--
作者：
Kosmalski, Marcin;Frankowski, Rafal;Ziolkowska, Sylwia;Rozycka-Kosmalska, Monika;Pietras, Tadeusz
非酒精性脂肪性肝病（NAFLD）是一种严重的健康问题，由于其高发病率和后果。鉴于现有的争议，仍在寻求NAFLD的新治疗选择。因此，我们综述的目的是评估最近发表的关于NAFLD患者治疗的研究。我们使用适当的术语检索PubMed数据库中的文章，包括“非酒精性脂肪肝”，“非酒精性脂肪肝”，“NAFLD”，“饮食”，“治疗”，“体力活动”，“补充”，“手术”，“序曲”和“指南”。最终分析使用了2020年1月至2022年11月期间发表的148项随机临床试验。结果显示，NAFLD治疗的显著益处不仅与地中海饮食有关，还与其他类型的饮食（包括低热量生酮、高蛋白、抗炎和全谷物饮食）有关，以及与选定的食品或补充剂有关。这组患者的显著益处也与适度的有氧体育训练有关。可用的治疗选择表明，首先，与减轻体重有关的药物以及降低胰岛素抵抗或脂质水平的药物和具有抗炎或抗氧化特性的药物的有用性。应强调度冷丁治疗和托福格列汀与吡格列酮联合治疗的有效性。根据最新研究结果，本文作者建议对NAFLD患者的治疗建议进行修订。
Non-alcoholic fatty liver disease (NAFLD) is a serious health problem due to its high incidence and consequences. In view of the existing controversies, new therapeutic options for NAFLD are still being sought. Therefore, the aim of our review was to evaluate the recently published studies on the treatment of NAFLD patients. We searched for articles in the PubMed database using appropriate terms, including “non-alcoholic fatty liver disease”, “nonalcoholic fatty liver disease”, “NAFLD”, “diet”, “treatment”, “physical activity”, “supplementation”, “surgery”, “overture” and “guidelines”. One hundred forty-eight randomized clinical trials published from January 2020 to November 2022 were used for the final analysis. The results show significant benefits of NAFLD therapy associated with the use of not only the Mediterranean but also other types of diet (including low-calorie ketogenic, high-protein, anti-inflammatory and whole-grain diets), as well as enrichment with selected food products or supplements. Significant benefits in this group of patients are also associated with moderate aerobic physical training. The available therapeutic options indicate, above all, the usefulness of drugs related to weight reduction, as well as the reduction in insulin resistance or lipids level and drugs with anti-inflammatory or antioxidant properties. The usefulness of therapy with dulaglutide and the combination of tofogliflozin with pioglitazone should be emphasized. Based on the results of the latest research, the authors of this article suggest a revision of the therapeutic recommendations for NAFLD patients.
登录
查看更多内容
DOI：
10.3390/antiox11071284
发表时间：
2022-06-28
期刊：
Antioxidants (Basel, Switzerland)
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.2
作者：
Caussy C;Aubin A;Loomba R
通讯作者：
Loomba R
影响因子：
3.6
作者：
Charatcharoenwitthaya P;Kuljiratitikal K;Aksornchanya O;Chaiyasoot K;Bandidniyamanon W;Charatcharoenwitthaya N
通讯作者：
Charatcharoenwitthaya N
影响因子：
5.4
作者：
Climax J;Newsome PN;Hamza M;Weissbach M;Coughlan D;Sattar N;McGuire DK;Bhatt DL
通讯作者：
Bhatt DL
影响因子：
15.9
作者：
Cohen, Catherine C.;Li, Kelvin W.;Vos, Miriam B.
通讯作者：
Vos, Miriam B.